计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E414173-5mg |
5mg |
现货 ![]() |
| |
| E414173-10mg |
10mg |
现货 ![]() |
| |
| E414173-25mg |
25mg |
现货 ![]() |
| |
| E414173-50mg |
50mg |
现货 ![]() |
| |
| E414173-100mg |
100mg |
现货 ![]() |
|
| 别名 | 依沃布替尼 (M-2951) |
|---|---|
| 英文别名 | DB15170 | EX-A2691 | 1-(4-(((6-Amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one | BCP28995 | SCHEMBL14165673 | GTPL9752 | 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-2-propen-1-one | EV |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Evobrutinib (M-2951) |
| 生化机理 | Evobrutinib(M-2951,MSC-2364447C)是一种高选择性 BTK 抑制剂,IC50 为 37.9 nM。它具有潜在的抗肿瘤活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酪氨酸蛋白激酶 BTK 抑制剂 |
| 产品介绍 |
Information Evobrutinib (M-2951) Evobrutinib (M-2951, MSC-2364447C) is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity. Targets BTK (Cell-free assay) 37.9 nM In vitro Evobrutinib can inhibit the activity of BTK and prevent the activation of the BCR signaling pathway. It is metabolized via hydroxylation, hydrolysis, O-dealkylation, glucuronidation, and GSH conjugation. |
| 纯度 | ≥98% |
| ALogP | 4.2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488202256 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one |
| INCHI | 1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29) |
| InChi Key | QUIWHXQETADMGN-UHFFFAOYSA-N |
| Smiles | C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N |
| Isomeric SMILES | C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N |
| 分子量 | 429.51 |
| Reaxy-Rn | 23237697 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23237697&ln= |
| 溶解性 | Solubility (25°C) In vitro |
|---|---|
| 分子量 | 429.500 g/mol |
| XLogP3 | 4.200 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 429.216 Da |
| 单同位素质量Monoisotopic Mass | 429.216 Da |
| 拓扑极表面积Topological Polar Surface Area | 93.400 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 595.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 | |
| 分析证书 | E414173 |
| 1. Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L, Bender AT et al.. (2019) Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.. J Immunol, 202 (10): (2888-2906). [PMID:30988116] |
| 2. Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS et al.. (2019) Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.. N Engl J Med, 380 (25): (2406-2417). [PMID:31075187] |
| 3. Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS et al.. (2019) Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.. J Med Chem, 62 (17): (7643-7655). [PMID:31368705] |